Biocomposites — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Biocomposites is a commercial-stage, privately-held medical device company with a 30-year legacy in calcium-based biomaterials. The company's product portfolio, led by the STIMULAN antibiotic carrier and SYNICEM bone cements/spacers, targets the significant clinical challenges of osteomyelitis, periprosthetic joint infections, and bone trauma. Recent strategic moves, including MDR certification in Europe, expansion into the US and Canadian markets, and a planned UK launch to address an NHS supply crisis, position the company for accelerated growth in the global orthobiologics and bone infection management markets.

Musculoskeletal InfectionsOrthopedic TraumaRevision Joint Arthroplasty

Technology Platform

Calcium-based biomaterial platform encompassing absorbable calcium sulfate antibiotic carriers, synthetic bone graft substitutes (hydroxyapatite, calcium phosphate composites), and antibiotic-loaded acrylic bone cements/spacers for localized drug delivery and bone regeneration.

Opportunities

The growing global crisis of antibiotic-resistant bone infections and periprosthetic joint infections creates a large and urgent need for effective local antibiotic delivery systems like STIMULAN and SYNICEM spacers.

Geographic expansion into major markets like the U.S., Canada, and a strategic push in the UK during a supply crisis present immediate avenues for significant revenue growth.

Risk Factors

Intense competition from large, established orthopedic device companies poses a constant threat to market share and pricing.

The company is also exposed to regulatory risks, particularly under the stringent EU MDR, and reimbursement challenges that can limit market access and adoption in key regions like the U.S.

Competitive Landscape

Biocomposites competes in the orthobiologics and bone infection management space against major orthopedic giants (e.g., Stryker with its Simplex cement, Zimmer Biomet, Johnson & Johnson DePuy Synthes) who offer similar antibiotic bone cements and spacers. It also competes with other companies specializing in calcium-based bone grafts (e.g., Medtronic, Baxter) and localized antibiotic delivery systems. Its differentiation lies in specific MDR certifications for broad-spectrum antibiotic use in soft tissue and bone, and its focus on ready-to-use spacer systems.

More companies in Regenerative Medicine →More companies in United Kingdom →